21.03.2019 MagForce AG  DE000A0HGQF5

DGAP-News: MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland


 

DGAP-News: MagForce AG / Key word(s): Agreement/Alliance
MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland

21.03.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland

  • First hospital outside of Germany to offer MagForce's NanoTherm therapy for the commercial treatment of brain tumor patients
  • NanoActivator at Independent Public Clinical Hospital No. 4 in Lublin, Poland is now ready for use after successful audit

Berlin, Germany and Nevada, USA, March 21, 2019 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that the installation of their mobile NanoTherm treatment center at the Independent Public Clinical Hospital No. 4 in Lublin, Poland, one of the most prestigious brain tumor treatment centers in Poland, has been completed. Following the successful final inspection of the center by the regulatory authority, Prof. Dr. hab. n. med. Tomasz Trojanowski, Head and Chairman of the Neurosurgery and Paediatric Neurosurgery Departments, State Consultant in Neurosurgery and a member of the Scientific Advisory Board for the Minister of Health, together with Prof. Dr. hab. n. med. Radoslaw Rola a new Head and Chairman of the Neurosurgery and Paediatric Neurosurgery Departments in SPSK4 in Lublin, and their renowned medical team of qualified and experienced doctors and nurses will perform the treatments.

The Independent Public Clinical Hospital No. 4 in Lublin is the first hospital outside of Germany to offer MagForce's NanoTherm therapy for the commercial treatment of brain tumor patients. The cooperation agreement, announced in June of 2018, is part of MagForce's European roll-out plan which aims to provide brain cancer patients with faster access to the therapy after diagnosis. To provide such accelerated treatment options, MagForce has developed a mobile solution for the placement of NanoActivator devices enabling the Company to place the devices more quickly and cost-effectively in further European countries by avoiding protracted construction and allowing for easy integration into the existing hospital infrastructure.

"Our team, Prof. Radoslaw Rola and I are extremely pleased with the successful completion of the installment and the positive audit from the regulatory authorities that will now allow us to commence commercial treatment, making NanoTherm therapy available to patients from Poland and other surrounding countries. The need for innovation in neuro-oncology is unmistakable as current treatments for brain tumors - including brain surgery, radiation and chemotherapy - often are not successful at eliminating all of the cancer cells from the brain. As one of the leading brain treatment centers in Poland, we are proud to be the first to offer an additional treatment option based on this highly innovative technology which has the potential to become a valuable option for patients diagnosed with the disease", said Prof. Trojanowski, Head and Chairman of the Departments of Neurosurgery and Paediatric Neurosurgery at Independent Public Clinical Hospital No. 4. "Due to the mobile solution offered by MagForce we were able to rapidly integrate the NanoActivator device into our existing hospital infrastructure, without the need for reconstruction. We are excited to continue working together with MagForce to make NanoTherm therapy available to patients suffering from this devastating disease."

The NanoTherm treatment center at the Independent Public Hospital No. 4 in Lublin will allow Polish patients to be treated with NanoTherm therapy in their home country. Due to the aggressive nature of glioblastoma, timely availability is a decisive factor in the treatment of brain tumors as there is only a narrow window for patients to receive treatment. With more than 50% of all patient inquiries who could qualify for NanoTherm therapy coming from, Poland, Poland, together with Germany and Italy make up a key market for MagForce's NanoTherm therapy within Europe.

The collaboration with Independent Public Clinical Hospital No. 4 in Lublin will be supported by the efforts of the Alivia Cancer Foundation, Poland. The Foundations's mission is to mobilize, empower and educate cancer patients as well as give them the tools and necessary means to make decisions regarding their own health.

"According to estimations, every fourth inhabitant of Poland is diagnosed with cancer during their life, and every fifth will die from it. Although therapeutic improvements have been achieved in recent years, access to new and innovative therapies as well as effective treatment options in Poland is still limited. As a result, the average Pole has a lower chance to survive 5 years with cancer compared to citizens of other European countries", said Bartosz Polinski, CEO of Alivia Cancer Foundation. "We are committed to support patients from Poland to gain access to novel approaches for the treatment of brain tumors. NanoTherm is a promising, novel approach to the treatment of brain cancer - stand alone or for the enhancement of effects of standard therapy. We are delighted that patients diagnosed with the disease will soon be able to have faster and easier access to this therapy."

About Independent Public Clinical Hospital No. 4 in Lublin, Poland
The Independent Public Clinical Hospital No. 4 in Lublin is the largest hospital in Lublin Province, comprising 22 highly specialised clinics and providing learning and research facilities for the Medical University in Lublin. The hospital serves patients from Lublin province as well as from other regions of the country and abroad. Over 1,600 patients receive surgery yearly, and about 6,000 consultations are given in an outpatient neurosurgical clinic.

In July 2010, due to high quality of the provided services and extensive treatment and diagnosis facilities, by the decision of the Minister of Health, the IPC Hospital no. 4 became a Trauma Centre for Lublin Province. In 2012 the hospital became one of the few hospitals in Poland that own a positron emission tomography scanner (PET).

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com


21.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

790041  21.03.2019 

fncls.ssp?fn=show_t_gif&application_id=790041&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 0,95 5,44 7,63 2,58 0,47 0,72 0,07 1,40
EBITDA1,2 -4,61 -1,48 -0,75 -1,32 -6,55 -6,74 7,43 -6,00
EBITDA-Marge3 -485,26 -27,21 -9,83 -51,16 -1.393,62 -936,11 10.614,29 -428,57
EBIT1,4 -4,89 -1,60 -0,97 -1,88 -7,46 -7,41 6,83 -6,60
EBIT-Marge5 -514,74 -29,41 -12,71 -72,87 -1.587,23 -1.029,17 9.757,14 -471,43
Jahresüberschuss1 -5,72 -1,63 -1,01 -1,55 -7,23 -7,47 4,36 -6,85
Netto-Marge6 -602,11 -29,96 -13,24 -60,08 -1.538,30 -1.037,50 6.228,57 -489,29
Cashflow1,7 -5,47 -6,79 -8,70 -5,13 -6,58 -5,34 -7,11 -6,50
Ergebnis je Aktie8 -0,24 -0,07 -0,04 -0.06 -0,28 -0,28 0,16 -0,22
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: AIOS

INVESTOR-INFORMATIONEN
©boersengefluester.de
MagForce
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0HGQF 4,320 Kaufen 119,41
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 32,63 0,000 -6,56
KBV KCV KUV EV/EBITDA
6,54 - 1.782,18 18,226
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 08.08.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.10.2019 20.06.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,04% -8,34% -17,24% -25,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MagForce AG  ISIN: DE000A0HGQF5 können Sie bei DGAP abrufen

Medtech , A0HGQF , MF6 , XETR:MF6